Xintela announces the appointment of Caroline Ehrencrona to a role responsible for the company's Clinical Development and Regulatory Affairs operations. Caroline Ehrencrona takes up the post on June 1 2016 and will strengthen Xintela's operations for upcoming clinical studies and will be responsible for the day-to-day contact with regulatory authorities.
Caroline Ehrencrona has more than ten years experience in the biotech industry and has most recently held a post as Project Director & QA Manager at TikoMed AB, Sweden. Caroline Ehrencrona has broad experience in both pre-clinical and early clinical research, with special emphasis on toxicology but also contact with regulatory authorities and quality assurance.
- For Xintela, it's really important to strengthen the team with experience of clinical development and regulatory issues so that we can effectively drive our projects forward into clinical phases. Caroline's broad experience of drug development and contact with regulatory authorities - in combination with her background as a researcher - are very valuable additions to the company, says Xintela's CEO Evy Lundgren-Åkerlund.
In addition to her broad experience from the biotech industry, Caroline Ehrencrona has a PhD in biomedical science and an MSc in chemistry from University of Kalmar. She has also research experience from the University of Lund.
- Xintela's strong portfolio and unique projects bode well for the future. Within the company, there is both the knowledge and competence needed to assert themselves in the field. I am looking forward to developing the clinical programme and to maintaining contact with the authorities to ensure that our studies and applications are approved. It will be very interesting to develop projects within the fields of regenerative medicine and cancer with the Xintela team, says Caroline Ehrencrona.
In addition to good planning, future clinical studies demand excellent contacts with regulatory authorities such as The Swedish MPA (Läkemedelsverket) and the European Medicines Agency (EMA). Caroline Ehrencrona,will work with the design and conduct of safety studies and future clinical programmes with CEO Evy Lundgren-Åkerlund and Research Director Carl-Magnus Högerkorp.
1 June 2016
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel:+46 70-329 18 71
E-mail: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se
Queries regarding trading with Xintela shares and warrants will be answered by the company's Certified Adviser, Consensus Asset Management AB. Telephone: +46 31-745 50 00.
Media and Investor Relations related queries should be directed to:
Adam Lindblom, Laika Consulting
Tel: +46 73-062 20 13
E-mail: adam.lindblom@laika.se
www.laika.se
The following documents can be retrieved from beQuoted
Xintela Pressrelease 2016-06-01 English.pdf
About Xintela
Xintela AB (publ) is a Swedish biomedical company active in the fields of regenerative medicine and cancer, with a focus on cartilage damage and brain tumours. The Company was founded in 2009, but research and development started in 2013. The key to Xintela's business is the Company's patented marker technology, XINMARK™. Xintela's markers are specific proteins which sit as "recognition flags" on certain cell surfaces. The markers make it possible to identify and quality assure cartilage cells and stem cells and also to select a certain type of stem cells which can develop into cartilage cells. Through this technology, Xintela can, in a unique way, quality assure stem cells for the repair of damaged cartilage. The XINMARK™-technology makes it also possible to direct antibody treatment to cells in glioblastoma brain tumours with the goal to slow down tumour growth. Xintela is listed on Nasdaq First North since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Consensus Asset Management AB.
Information submitted for publication 1 June 2016 08.30 CET
